CCM Biosciences Inc. has launched with a focus on discovering and developing novel drugs, including small molecules, gene therapies, biologics and nanomedicines, and companion diagnostic tests.

KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can't bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.

Peptigrowth Inc. and Orizuru Therapeutics Inc. have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of a regenerative medicine product being developed by Orizuru.

3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).

Chiesi Global Rare Diseases, a Chiesi Farmaceutici SpA business unit, has signed a co-development agreement with Aliada Therapeutics Inc.

Alexion, Astrazeneca Rare Disease, part of Astrazeneca plc, has entered a definitive purchase and license agreement for a portfolio of preclinical gene therapy programs and enabling technologies from Pfizer Inc.

An mRNA vaccine candidate that acts in the liver by recruiting memory T cells could be the key against malaria, according to a study in mice that demonstrated its efficacy by including a natural killer T (NKT) cell agonist.

The Hubmap consortium has released the atlas of three human organs, a cell-by-cell map based on overlaid images from microscopy and molecular data. Maps of the intestine, the kidney and the placenta, published in three simultaneous articles, have revealed the cellular morphology and architecture of these organs in healthy and diseased conditions.